Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
lung cancer
UK Users with Small Cell Lung Cancer
By Dross at 2008-02-28 02:14
 

For those of you with Small Cell Lung Cancer located in the UK, Please read on, a clinical trial organization is searching for patients:

 

We are currently seeking patients who have been diagnosed with Small Cell
Lung Cancer (later stages). This is an informal discussion and the
patient is free to disclose as much or as little information as they wish.
We would not expect the patient to discuss anything they are not
comfortable in doing so and the patient is free to end the interview at
any stage.

We abide by the Data Protection Act and a range of industry codes of
conduct (including MRS, ESOMAR guidelines), which means the research is
entirely confidential and that participants are guaranteed anonymity (i.e.
their name/address will at no point be passed on to any third parties).

read more | 979 reads

UK Users with Small Cell Lung Cancer
By Dross at 2008-02-22 01:12
 

We are currently seeking patients who have been diagnosed with Small Cell
Lung Cancer (later stages).  This is an informal discussion and the
patient is free to disclose as much or as little information as they wish.
 We would not expect the patient to discuss anything they are not
comfortable in doing so and the patient is free to end the interview at
any stage.

The interviewing group abides by the Data Protection Act and a range of industry codes of
conduct (including MRS, ESOMAR guidelines), which means the research is
entirely confidential and that participants are guaranteed anonymity (i.e.
their name/address will at no point be passed on to any third parties).

The interviewer will meet the patient at a time and place convenient to
the patient.  The aim of this research will be to use the information to
help our client develop new treatments and support services, which are
able to meet their needs.

As a thank you for your referral and the patient’s participation you will be provided with the following incentive:

Incentive for the patient for a 1-hour interview:       £50
Incentive for the patient for a 2-hour interview:       £150

read more | 1134 reads

Scientists at Cold Spring Harbor Laboratory Identify Cells That Promote Formation of Lethal Lung Metastases
By Dross at 2008-01-11 04:51
 
Cold Spring Harbor, NY – Cancer patients usually ask what can be done after a primary tumor has already spread, or metastasized, to other organs. In many cases, they learn, little can be done. Hence the importance of a discovery by scientists at Cold Spring Harbor Laboratory (CSHL) of a type of cell that regulates the transformation of small, dormant lung metastases into large, aggressive metastases – the kind that kill cancer patients.
 
 

The cells that promote the metastaticterm transformation are called endothelial progenitor cells, or EPCs, and are found in the bone marrow. The CSHL research team reports in the January 11 issue of Science that EPCs regulate an “angiogenic switch” – a key mechanism that causes formation of blood vessels in tumors and triggers tumor growth.

“A majority of malignant primary tumors have already spread to other organs by the time they are clinically diagnosed,” noted Vivek Mittal, Ph.D., head of the CSHL research team and corresponding author of the Science paper. “Current efforts are focused on preventing metastatic spread, yet, paradoxically, insights have been lacking on how dormant metastatic lesions, after they have colonized distant organs, grow into large, lethal lesions.”

“Our study has focused on cells from primary tumors in mice that have spread and established micrometastases in secondary organs such as the lung,” said Dingcheng Gao, Ph.D., a CSHL postdoctoral fellow and lead author of the Science paper. “We’ve dissected the heart of the angiogenic switch and demonstrated that micrometastases recruit EPCs from the bone marrow. These EPCs, in turn, regulate the angiogenic switch that activates blood-vessel growth and transforms these dormant lesions into life-threatening macrometastases.”

Drs. Mittal, Gao and colleagues at CSHL showed in experimental mice that levels of a protein called Id-1 increase dramatically in EPCs when tumors are present. By using a technique called RNA interference, or RNAi, to block the expression of Id-1 in living animals, the team was able to prevent mobilization of EPCs to the site of metastasistermterm, and thereby inhibit the angiogenic switch. This, in turn, interrupted the process in mice by which micrometastases are converted into lethal macrometastases. Notably, increased survival was noted in the tumor-bearing animals that were treated with this method. The next step is to perform a similar study in humans.

“This study has raised the prospect of a novel therapeutic target, and suggests that selective targeting of EPCs, perhaps in combination with chemotherapyterm, may prove to be a clinically feasible approach in the treatment of people diagnosed with cancer that has metastasized to the lungs,” Dr. Mittal said.

“Past experiences have highlighted the challenges associated with therapies that target genetically mutant cancer cells. For instance, we know that cancer cells develop resistance to chemotherapeutic agents. We feel that approaches based on targeting the genetically stable components of the tumor microenvironment, such as the EPCs, need to be further explored for effective treatment of cancer.”

“Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis” appears in Science on January 11. The compete citation is as follows: Dingcheng Gao, Daniel J. Nolan, Albert S. Mellick, Kathryn Bambino, Kevin McDonnell and Vivek Mittal. The paper is available online at: http://www.sciencemag.org/cgi/content/abstract/319/5860/195

CSHL is a private, non-profit research and education institution dedicated to exploring molecular biology and genetics in order to advance the understanding and ability to diagnose and treat cancers, neurological diseases, and other causes of human suffering.

1267 reads

New report estimates 12 million cancer cases worldwide
By Dross at 2007-12-17 22:06
 

ATLANTA, December 17, 2007—A new American Cancer Society report estimates that there will be over 12 million new cancer cases and 7.6 million cancer deaths (about 20,000 cancer deaths a day) worldwide in 2007. The estimate comes from the first-ever Global Cancer Facts & Figures, the latest addition to the American Cancer Society’s family of Facts & Figures publications. The report estimates that 5.4 million of those cancers and 2.9 million deaths will occur in economically developed countries, while 6.7 million cases and 4.7 million deaths will occur in economically developing countries. These projections were based on incidence and mortality data from the Globocan 2002 database compiled by the International Agency for Research on Cancer (IARC).

read more | 1137 reads

Study points to possibility of blood test to detect lung cancer
By Dross at 2007-12-09 01:51
 

DURHAM, N.C. -- A test for four blood proteins may provide a less-invasive follow-up for patients who have suspicious lesions on chest radiographs or computerized tomography (CT) scans, according to a new study led by Duke University Medical Center researchers.

“CT scans have a very high false positive rate when trying to discover lung cancer,” said Edward Patz, Jr., M.D., a radiologist at Duke and lead investigator on the study. “What that leads to is several follow-up imaging studies or invasive procedures like biopsy, which have risks of their own. This study is the first step in developing a test that would allow us to sample a patient’s blood and determine whether more invasive testing and treatment are necessary.”

read more | 5 comments | 1216 reads

M. D. Anderson research links diet, gardening and lung cancer risk
By Dross at 2007-12-09 01:51
 

PHILADELPHIA - By simply eating four or more servings of green salad a week and working in the garden once or twice a week, smokers and nonsmokers alike may be able to substantially reduce the risk of developing lung cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

"This is the first risk prediction model to examine the effects of diet and physical activity on the possibility of developing lung cancer," says Michele R. Forman, Ph.D., lead author of the study and a professor in M. D. Anderson's Department of Epidemiology. Forman presented study results at the American Association for Cancer Research "Frontiers in Cancer Prevention Research" meeting Dec. 7 in Philadelphia, Pa. The data are from an ongoing M. D. Anderson case-control lung cancer study involving more than 3,800 participants. Separate epidemiologic risk assessment models were developed for current and former smokers as well as for those who have never smoked ("never smokers").

read more | 893 reads

lung cancer diagnoses can be significantly improved and followed with PET scanning
By Dross at 2007-11-28 20:54
 

A review that was released today by the Jounral of the National Cancer Institute concluded today that  Positron emission tomography (PET) is a useful tool for patients.

The review conducted by the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care led by a Sunnybrook researcher, Dr. Yee Ung, evaluates the accuracy and utility of 18-fluorodeoxyglucose PET (18FDG-PET) in the diagnosis and staging of lung cancer.

“Lung cancer remains the leading cause of cancer-related death and early diagnosis provides the best chance for long term survival,” says Dr. Ung, chair, Lung Cancer Site Group, Odette Cancer Centre, Sunnybrook. “It is our hope this systematic review contributes to clinical guideline discussions exploring the potential of PET as part of standard preoperative work-up - along with computed tomography (CT) - to further enhance assessment of early-stage lung cancer.”

read more | 980 reads

Preventing lung scarring may extend lives of lung cancer patients
By Dross at 2007-10-30 01:56
 

Researchers have found that using a special type of drug called a pharmaceutical monoclonal antibodyterm to block the integrin beta6-TGF-beta pathway prevents a serious side effect of radiation therapy for lung cancer patients – pulmonary fibrosis (scarring of the lungs), thereby extending patients’ lives and improving their quality of life, according to a study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.

“The toxicity of pulmonary fibrosis limits the amount of the radiation dose that can be safely given to patients,” said Simon Cheng, M.D., Ph.D., an author of the study and a radiation oncologist at New York University Medical Center in New York. “These study results may lead to more effective radiation therapies for advanced lung cancer, which is the leading cause of cancer deaths in the U.S.”

read more | 3 comments | 1017 reads

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
By Dross at 2007-10-20 03:55
 

Pharmion Corporation (NASDAQ:PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapyterm for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year. "The treatment of small cell lung cancer is extremely challenging, given the limited therapeutic options available," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study. "Preliminary data suggest that amrubicin could represent a significant improvement in the treatment of small cell lung cancer, for which there have been no major medical advances in more than 20 years."

read more | 2 comments | 1447 reads

New technique detects specific chromosomal damage, may indicate lung cancer risk
By Dross at 2007-08-31 20:17
 

A new technique could pave the way toward screening people at risk for lung cancer for the genetic changes that may foreshadow malignancies, researchers from the University of Colorado say.

“The most successful way to reduce mortality in cancer is prevention,” said researcher Wilbur A. Franklin, M.D., Professor of Pathology at the University of Colorado Health Sciences Center. “Our goal would be to develop screening techniques for lung lesions that could enable us to identify precancerous changes.”

The study appears in the September 1, 2007 issue of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

read more | 846 reads

Defects in critical gene lead to accelerated lung tumor growth
By Dross at 2007-08-06 23:38
 

CHAPEL HILL – Cancer causing mutations occur in our bodies every day – but luckily, we have specific genes that recognize these malignant events and keep cells from growing out of control. Only a few of these genes – called tumor suppressors – are currently known.

Now scientists at the University of North Carolina at Chapel Hill School of Medicine and Harvard Medical School have added to the list another powerful tumor suppressor, a gene called LKB1. Their research indicates that this gene is mutated in almost a quarter of all human lung cancers. In mice, these mutations result in tumors that are more aggressive and more likely to spread throughout the body.

read more | 3 comments | 1222 reads

Kids show signs of addiction after inhlaing one cigarette
By Dross at 2007-07-06 13:53
 

WORCESTER, Mass. -- A new study published in the Archives of Pediatric and Adolescent Medicine shows that 10 percent of youth who become hooked on cigarettes are addicted within two days of first inhaling from a cigarette, and 25 percent are addicted within a month. The study found that adolescents who smoke even just a few cigarettes per month suffer withdrawal symptoms when deprived of nicotine, a startling finding that is contrary to long-held beliefs that only people with established smoking habits of at least five cigarettes per day experience such symptoms.

The study monitored 1,246 sixth-grade students in six Massachusetts communities over four years. Students were interviewed frequently about smoking and symptoms of addiction, such as difficulty quitting, strong urges to smoke, or nicotine withdrawal symptoms such as cravings, restlessness, irritability, and trouble concentrating. Of those who were hooked, half were already addicted by the time they were smoking seven cigarettes per month. As amazing as it may seem, some youth find they are unable to quit smoking after just a few cigarettes. This confirms an earlier study by the same researchers.

read more | 1154 reads

New Cancer Treatment Adds to Survival Rates in Lung Cancer Patients
By Dross at 2007-07-03 10:57
 

Patients with inoperable non-small cell lung cancer who receive an initial high dose of chemotherapyterm before their treatment begins can expect an increase in overall survival, according to a study in the July 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Non-small cell lung cancer is the most common type of lung cancer in the United States, according to the American Cancer Society. Treatment for lung cancer depends on the size and location of the tumor, the age and medical history of the patient and the type of cancer to be treated. Patients will often consult with a few medical professionals to determine the best course of treatment for them. In cases where the patient is not eligible for surgery or the tumor's location makes surgery impossible, a combination of chemotherapy and radiation, sometimes called chemoradiation, is suggested.

read more | 1662 reads

Surgeons say minimally invasive lung surgery should be standard care
By Dross at 2007-06-29 22:20
 

Major U.S. academic medical centers can successfully—and safely—integrate minimally invasive lung surgery into their training programs with a standardized, step-by-step plan, according to University of Cincinnati (UC) thoracic surgeons.

It’s estimated that only about 10 percent of all lung cancer operations nationwide are done with minimally invasive techniques, but more than half the patients who need the surgery would qualify for the less invasive procedure, which results in faster recovery time and less pain for patients.

The minimally invasive lung surgery, known as a thoracoscopic lobectomy, is done through several small incisions, versus a major chest incision, and requires no rib spreading. UC is one of only a handful of academic medical centers actively training surgeons to perform the procedure.

read more | 5 comments | 876 reads

Department: Office of Communications (with news releases)
By Dross at 2007-06-20 04:27
 

Adding more good news to last week’s announcement that Nexavar® (sorafenibterm) may be the first effective treatment for advanced liver cancer, researchers at the Lombardi Comprehensive Cancer Center at Georgetown University have uncovered a new molecular mechanism that may “spontaneously” cause liver cancer.

Part of the well-known TGF-ß tumor suppressor pathway, the molecule disappears in the cells of nearly 90 percent of human hepatocellular cancers, the most common type of liver cancer. Lopa Mishra, MD, professor and vice chair in the department of surgery at Georgetown University Medical Center, showed that loss of only one copy of the embryonic liver fodrin, or ELF gene, can result in spontaneous development of liver cancer in human cell cultures and in vivo models.

read more | 1917 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 08:06 AM.